UNIVERSITY OF KANSAS

Hispanic women face mixed body image messages during holidays, with encouragement to eat more and warnings against overeating. The study highlights the need for culturally adapted body functionality programs to improve body image and address eating disorders, which are underrepresented in research.

New drug therapy Vyalev, developed by AbbVie with input from KU's Valentino Stella, aims to improve Parkinson’s treatment with a wearable pump delivering consistent L-dopa/carbidopa therapy. FDA approved in 2024, Vyalev showed superior motor symptom control in clinical trials. Stella, with a history of inventing FDA-approved drugs, highlights the impact of his work on patients' lives.

The Wichita Biomedical Campus, a collaboration between Wichita State University, University of Kansas, and WSU Tech, is progressing steadily. It aims to transform health care education and research in Kansas, with construction updates showing on-schedule work despite weather challenges. Future plans include a feasibility study for Kansas' first dental school and the launch of the Institute for Rehabilitation Medicine and Assistive Technology. Additional funding supports audiology education and clinical care, enhancing research and patient services.

University of Kansas CFO Jeff DeWitt announced 443 new apartment-style housing beds in the Gateway District Project's next phase, addressing 98% occupied KU housing. The project includes retail, office, and restaurant spaces on ground floors, with plans for 1,000 parking spots, a Marriott hotel, and a Gateway Plaza. Phase II construction begins post-2025 football season, targeting completion by 2027.

University of Kansas leaders unveiled plans for the second phase of the Gateway District project, focusing on new retail, dining, parking, residential facilities, and a hotel to benefit the campus community and drive economic growth. The project aims to attract out-of-town guests and enhance Lawrence's status as a dynamic college town.

Scientists developed a biotechnological process to recycle carbon fiber reinforced polymers, recovering carbon fiber with mechanical properties comparable to virgin materials. The process uses a genetically modified fungus to produce a valuable chemical compound from matrix breakdown products, potentially revolutionizing carbon fiber recycling.

Trump's tariffs may increase drug prices; inflation rose as expected; FBI raided Polymarket CEO's home; Bitcoin prices hit $90,000; Dogecoin rose; AI can write code; solar, wind, and battery projects expected to grow; Trump nominated Gaetz and Gabbard; Republicans control House; E. Coli outbreak linked to McDonald's; prominent X accounts leaving; Tucker Carlson launches nicotine pouches; Amazon Haul competes with Shein and Temu; small businesses can win holiday sales; Tyson and Paul to fight on Netflix.

A study on financial toxicity in testicular cancer treatment uses large language machine learning models and Markov modeling to predict patterns in stage IIA non-seminoma patients, comparing RPLND and chemotherapy. The research shows RPLND has higher initial costs but lower long-term financial toxicity compared to chemotherapy, which has increasing financial burden over time. The study emphasizes the importance of discussing financial toxicity with patients and the need for better support resources and prospective trials to validate findings across medical specialties.

Biogen's Q3 2024 earnings call highlights progress in Alzheimer's treatment Leqembi, with global revenue growth of 66% QoQ, and the launch of Skyclarys in 15 markets outside the U.S. CEO Chris Viehbacher discusses strategic growth objectives and the potential of the late-stage pipeline, including dapirolizumab in lupus and BIIB080 in Alzheimer's, projecting a cumulative peak sales potential of $14 billion. CFO Mike McDonnell reports total revenue of $2.5 billion, down 3%, and raises full-year 2024 non-GAAP diluted EPS guidance to $16.10-$16.60. The call also addresses questions on commercial strategies, pipeline developments, and financial outlook.

Bickel established the International Quit & Recovery Registry at Virginia Tech, aiding scientific understanding of long-term recovery. The registry now includes over 10,000 participants from 60 countries. Bickel also developed the Experimental Tobacco Marketplace to study health behaviors influenced by policy. His legacy includes BEAM Diagnostics, a digital screening tool for behavioral health conditions. Bickel's career was marked by collaboration, mentorship, and numerous awards. Despite a terminal cancer diagnosis, he continued his research, co-authoring studies on addiction until his final months.